Treatment of malignant pleural effusion with the trifunctional antibody catumaxomab (Removab) (anti-EpCAM x Anti-CD3): results of a phase 1/2 study. (Q51803475)
Jump to navigation
Jump to search
scientific article published in February 2009
Language | Label | Description | Also known as |
---|---|---|---|
English | Treatment of malignant pleural effusion with the trifunctional antibody catumaxomab (Removab) (anti-EpCAM x Anti-CD3): results of a phase 1/2 study. |
scientific article published in February 2009 |
Statements
Treatment of malignant pleural effusion with the trifunctional antibody catumaxomab (Removab) (anti-EpCAM x Anti-CD3): results of a phase 1/2 study (English)
Martin Sebastian
Philipp Kiewe
Daniel Brust
Christian Peschel
Folker Schneller
Karl-Heinz Rühle
Georg Nilius
Ralf Ewert
Sven Lodziewski
Bernward Passlick
Wulf Sienel
Rainer Wiewrodt
Michael Jäger
Horst Lindhofer
Hilke Friccius-Quecke
Alexander Schmittel
1 February 2009